Astrazeneca PLC 6-K, filed Mar 10, 2020
Astrazeneca PLC (AZN)
6-K
2020-03-10
For: 2020-03-10
View Original
Added on
April 02, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on March 10, 2020.
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March
2020
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Director/PDMR Shareholding
10 March 2020 07:00 GMT
Transactions by Persons Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announced that, on 6 March 2020,
certain Persons Discharging Managerial Responsibilities of the
Company (PDMRs) were granted awards of the Company's ordinary
shares of $0.25 each (Ordinary Shares) under the terms of the
AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca
Performance Share Plan (AZPSP), as detailed in the table
below.
|
PDMR
|
Ordinary Shares granted under the AZDBP
|
Ordinary Shares granted under the AZPSP
|
Award price per Ordinary Share
|
|
Pascal Soriot
|
8,734
|
87,346
|
£73.76
|
|
Marc Dunoyer
|
4,323
|
41,501
|
£73.76
|
The AZDBP award represents the portion of each PDMR's annual bonus
for 2019 that they are required to defer into shares. The Ordinary
Shares granted under the AZDBP are subject to a three-year holding
period and are due to vest on the third anniversary of
grant.
The AZPSP award is subject to a combination of performance measures
focused on scientific, commercial and financial performance
assessed over a three-year performance period (1 January 2020 to 31
December 2022). The Ordinary Shares granted under the AZPSP are
subject to a two-year holding period following the performance
period, and are due to vest on the fifth anniversary of
grant.
Details of the performance measures attached to the AZPSP award can
be found in the Directors' Remuneration Report within the
AstraZeneca Annual Report and Form 20-F Information 2019, which is
available on the Company's website at
www.astrazeneca.com/annualreport2019.
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
||
|
a)
|
Name
|
Pascal Soriot
|
|
|
2
|
Reason for the notification
|
||
|
a)
|
Position/status
|
Chief Executive Officer
|
|
|
b)
|
Initial notification /Amendment
|
Initial notification
|
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
AstraZeneca PLC
|
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
|
|
b)
|
Nature of the transaction
|
Grants of share awards under the AstraZeneca Performance Share Plan
and the AstraZeneca Deferred Bonus Plan
|
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
£73.76
|
96,080
|
||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
|
|
e)
|
Date of the transaction
|
6 March 2020
|
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
||
|
a)
|
Name
|
Marc Dunoyer
|
|
|
2
|
Reason for the notification
|
||
|
a)
|
Position/status
|
Chief Financial Officer
|
|
|
b)
|
Initial notification /Amendment
|
Initial notification
|
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
AstraZeneca PLC
|
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
|
|
b)
|
Nature of the transaction
|
Grants of share awards under the AstraZeneca Performance Share Plan
and the AstraZeneca Deferred Bonus Plan
|
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
£73.76
|
45,824
|
||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
|
|
e)
|
Date of the transaction
|
6 March 2020
|
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal and Metabolism, and Respiratory.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients
worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
|
Media Relations
|
|
|
|
Gonzalo
Viña
|
|
+44 203 749 5916
|
|
Rob
Skelding
|
Oncology
|
+44 203 749 5821
|
|
Rebecca
Einhorn
|
Oncology
|
+1 301 518 4122
|
|
Matt
Kent
|
BioPharmaceuticals
|
+44 203 749 5906
|
|
Angela
Fiorin
|
BioPharmaceuticals
|
+44 1223 344 690
|
|
Jennifer
Hursit
|
Other
|
+44 203 749 5762
|
|
Christina
Malmberg Hägerstrand
|
Sweden
|
+46 8 552 53 106
|
|
Michele
Meixell
|
US
|
+1 302 885 2677
|
|
Investor Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203 749 5712
|
|
Henry
Wheeler
|
Oncology
|
+44 203 749 5797
|
|
Christer
Gruvris
|
BioPharmaceuticals
(Cardiovascular, Metabolism)
|
+44 203 749 5711
|
|
Nick
Stone
|
BioPharmaceuticals (Renal) Environmental, Social and
Governance
|
+44 203 749 5716
|
|
Josie
Afolabi
|
BioPharmaceuticals (Respiratory)
|
+44 203 749 5631
|
|
Tom
Waldron
|
Other medicines
|
+44 7385 033 717
|
|
Craig
Marks
|
Finance
Fixed income
|
+44 7881 615 764
|
|
Jennifer
Kretzmann
|
Corporate access
Retail investors
|
+44 203 749 5824
|
|
US
toll-free
|
|
+1 866 381 72 77
|
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
10 March
2020
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|